176 related articles for article (PubMed ID: 29581296)
1. Recombinant immunotoxins with albumin-binding domains have long half-lives and high antitumor activity.
Wei J; Bera TK; Liu XF; Zhou Q; Onda M; Ho M; Tai CH; Pastan I
Proc Natl Acad Sci U S A; 2018 Apr; 115(15):E3501-E3508. PubMed ID: 29581296
[TBL] [Abstract][Full Text] [Related]
2. Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A.
Kaplan G; Lee F; Onda M; Kolyvas E; Bhardwaj G; Baker D; Pastan I
Toxins (Basel); 2016 Jul; 8(8):. PubMed ID: 27463727
[TBL] [Abstract][Full Text] [Related]
3. Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity.
Zheng Z; Okada R; Kobayashi H; Nagaya T; Wei J; Zhou Q; Lee F; Bera TK; Gao Y; Kuhlman W; Tai CH; Pastan I
Mol Cancer Ther; 2020 Mar; 19(3):812-821. PubMed ID: 31871266
[TBL] [Abstract][Full Text] [Related]
4. Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A-Based Immunotoxins.
Liu X; Müller F; Wayne AS; Pastan I
Mol Cancer Ther; 2016 May; 15(5):1053-62. PubMed ID: 26939705
[TBL] [Abstract][Full Text] [Related]
5. Novel Anti-Mesothelin Nanobodies and Recombinant Immunotoxins with
Nguyen MQ; Kim DH; Shim HJ; Ta HKK; Vu TL; Nguyen TKO; Lim JC; Choe H
Mol Cells; 2023 Dec; 46(12):764-777. PubMed ID: 38052492
[TBL] [Abstract][Full Text] [Related]
6. Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity.
Mazor R; Onda M; Park D; Addissie S; Xiang L; Zhang J; Hassan R; Pastan I
Oncotarget; 2016 May; 7(21):29916-26. PubMed ID: 27167198
[TBL] [Abstract][Full Text] [Related]
7. Immunotoxin SS1P is rapidly removed by proximal tubule cells of kidney, whose damage contributes to albumin loss in urine.
Liu XF; Wei J; Zhou Q; Molitoris BA; Sandoval R; Kobayashi H; Okada R; Nagaya T; Karim B; Butcher D; Pastan I
Proc Natl Acad Sci U S A; 2020 Mar; 117(11):6086-6091. PubMed ID: 32123080
[TBL] [Abstract][Full Text] [Related]
8. Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer.
Cerise A; Bera TK; Liu X; Wei J; Pastan I
Clin Colorectal Cancer; 2019 Sep; 18(3):192-199.e1. PubMed ID: 31345777
[TBL] [Abstract][Full Text] [Related]
9. Preclinical development of anti-BCMA immunotoxins targeting multiple myeloma.
Shancer Z; Williams M; Igelman A; Nagata S; Ise T; Pastan I; Bera TK
Antib Ther; 2018 Jun; 1(1):19-25. PubMed ID: 30272049
[TBL] [Abstract][Full Text] [Related]
10. Designing the furin-cleavable linker in recombinant immunotoxins based on Pseudomonas exotoxin A.
Weldon JE; Skarzynski M; Therres JA; Ostovitz JR; Zhou H; Kreitman RJ; Pastan I
Bioconjug Chem; 2015 Jun; 26(6):1120-8. PubMed ID: 25997032
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of Immunotoxins Containing
Mazor R; Pastan I
Front Immunol; 2020; 11():1261. PubMed ID: 32695104
[TBL] [Abstract][Full Text] [Related]
12. Methylation-associated partial down-regulation of mesothelin causes resistance to anti-mesothelin immunotoxins in a pancreatic cancer cell line.
Hollevoet K; Mason-Osann E; Müller F; Pastan I
PLoS One; 2015; 10(3):e0122462. PubMed ID: 25803818
[TBL] [Abstract][Full Text] [Related]
13. Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL.
Li R; Yang H; Jia D; Nie Q; Cai H; Fan Q; Wan L; Li L; Lu X
J Control Release; 2016 Apr; 228():96-106. PubMed ID: 26951928
[TBL] [Abstract][Full Text] [Related]
14. Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain.
Liu H; Seijsing J; Frejd FY; Tolmachev V; Gräslund T
Int J Oncol; 2015 Aug; 47(2):601-9. PubMed ID: 26046132
[TBL] [Abstract][Full Text] [Related]
15. Anticancer Effects of Mesothelin-Targeted Immunotoxin Therapy Are Regulated by Tyrosine Kinase DDR1.
Ali-Rahmani F; FitzGerald DJ; Martin S; Patel P; Prunotto M; Ormanoglu P; Thomas C; Pastan I
Cancer Res; 2016 Mar; 76(6):1560-8. PubMed ID: 26719540
[TBL] [Abstract][Full Text] [Related]
16. Low-Dose Methotrexate Prevents Primary and Secondary Humoral Immune Responses and Induces Immune Tolerance to a Recombinant Immunotoxin.
King EM; Mazor R; Çuburu N; Pastan I
J Immunol; 2018 Mar; 200(6):2038-2045. PubMed ID: 29431691
[TBL] [Abstract][Full Text] [Related]
17. Fusion of an albumin-binding domain extends the half-life of immunotoxins.
Guo R; Guo W; Cao L; Liu H; Liu J; Xu H; Huang W; Wang F; Hong Z
Int J Pharm; 2016 Sep; 511(1):538-549. PubMed ID: 27457423
[TBL] [Abstract][Full Text] [Related]
18. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein.
Hopp J; Hornig N; Zettlitz KA; Schwarz A; Fuss N; Müller D; Kontermann RE
Protein Eng Des Sel; 2010 Nov; 23(11):827-34. PubMed ID: 20817756
[TBL] [Abstract][Full Text] [Related]
19. Domain II of
Müller F; Cunningham T; Beers R; Bera TK; Wayne AS; Pastan I
Toxins (Basel); 2018 May; 10(5):. PubMed ID: 29883379
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies.
Müller F; Stookey S; Cunningham T; Pastan I
Oncotarget; 2017 May; 8(19):30644-30655. PubMed ID: 28423727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
